Science

Not waiting for nature-positive standards, UK multinational GSK is taking action and a leadership role in the pharma and biotech sector. By Alastair Morton and Ellie Fallon.

Professor Shuji Nakamura’s Nobel Prize-winning invention was the achievement of years of solitary, dedicated research. By Jessica Gang.

Science-based targets revolutionized business action on climate. They’re poised to do the same for nature. Leaders from three businesses in the vanguard of this dizzyingly complex—and critical—work talk about shaping the new standards.

At a time when so many stories about the oceans are dispiriting, Brunswick spoke with five companies, large and small, that inspire a sense of hope.

PepsiCo’s Chief Sustainability Officer and Executive Vice President Jim Andrew talks to Brunswick’s Brendan Riley and Lucy Parker about the company’s actions and commitments to regenerative agriculture.

Dr. Andrea Maier chooses Singapore as a base of operation for groundbreaking work in healthy longevity research and clinical practice. By Brunswick’s Sunitha Chalam.

Brunswick’s Ben Hirschler describes taking part in a COVID-19 vaccine trial as part of the historic global effort to halt the disease.

The New Nature Economy series, produced by the World Economic Forum, lays out the risks and opportunities for business. By Akanksha Khatri and Lucy Almond.

Genevieve Bell, founding Director of the Australian National University’s School of Cybernetics, talks to Brunswick’s Alice Gibb.

The most vulnerable organizations may not understand their exposure to online attackers. CEO Stéphane Duguin tells Brunswick’s Mark Seifert how CyberPeace is building NGO defenses.

Takeshi Hakamada talks about founding ispace and leading his company, through success and failure, toward its lunar aspirations.

Clinical trial diversity must improve to ensure drugs work for all. By Ben Hirschler.